Clinical Trial Update: Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating radiotherapy with irinotecan and apatinib followed by PD-1 antibody and apatinib for advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Apatinib (apatinib)
• Irinotecan (Irinotecan)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Solid Tumor | Phase 2 | Status: UNKNOWN